Erasca

Erasca is a clinical-stage precision oncology company on a mission “to erase cancer,” focused on therapies that shut down the RAS/MAPK signaling cascade — one of the most commonly mutated cancer pathways. Its pipeline comprises targeted programs that attack the RAS/MAPK pathway at multiple nodes, with the goal of addressing cancers driven by these mutations (a pathway that affects roughly 5.5 million people worldwide each year). By developing precision small molecules and combination strategies, Erasca aims to deliver transformative treatments that improve outcomes across a broad range of devastating cancers.